Does everyone lose weight on Mounjaro — and what affects your results?

Step 1: understand what the trial data does (and doesn't) tell you

The SURMOUNT-1 trial enrolled 2,539 adults with obesity and followed them for 72 weeks. At the 15mg dose, average body-weight reduction was around 20–21%, with some analyses putting it slightly higher. That figure is a mean across thousands of people. The range around it was wide, some participants lost considerably more, others noticeably less. A trial average is the right starting point for setting expectations, but it is not a personal forecast.

The trial results are published in the New England Journal of Medicine (SURMOUNT-1, 2022) and form the evidence base for NICE's recommendation. Reading those numbers as a ceiling or a guarantee misses the point. They describe what happened, on average, under controlled conditions with structured lifestyle support, not what will happen to you specifically.

One detail worth knowing: participants who reached higher doses tended to see greater average loss. That is partly why treatment starts at 2.5mg and is titrated gradually. The starter dose is there to let your body adjust, not to produce the bulk of the weight loss. Many people notice little change in the first few weeks, which is expected.

Step 2: the factors that most influence whether Mounjaro works for you

Several things shape individual response, and most of them are knowable before you start. Baseline BMI matters: people with higher starting weights tend to see larger absolute losses, though percentage losses can be similar across groups. Metabolic health plays a role too, insulin resistance, hormonal conditions such as hypothyroidism, and some medications can affect how effectively the body responds to tirzepatide.

Adherence is arguably the biggest variable within someone's control. Missing doses, not adjusting eating habits, or stopping titration early all reduce the effect. The practical steps that support weight loss on Mounjaro (eating enough protein, staying well hydrated, and building in movement) are not optional extras. They are part of what the trials measured.

Side effects also matter. Nausea is common in the early weeks and can make eating less feel natural anyway, but if it becomes severe enough to affect nutrition and hydration, that is a clinical conversation, not something to push through alone. Our prescribers review every patient's progress, not just their starting point.

If you are curious about what drives the medicine's appetite effects at a biological level, the mechanism behind tirzepatide's action is worth understanding before you start.

Step 3: what happens if results are slower than expected

Slower early progress does not necessarily mean Mounjaro is not working. Weight loss on this treatment is rarely linear. Some people see little movement in the first month, then more consistent loss from the second pen onwards. The early weeks on Mounjaro are often about tolerability rather than rapid weight change.

The NHS and NICE are clear on the review point: if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing the medicine should be reassessed. That is not a failure, it is a clinical checkpoint, and it exists because the medicine genuinely does not produce a meaningful response in a minority of people. The right conversation at that point is with your prescriber, not a forum.

Worth noting for context: weekly weight changes on Mounjaro are unpredictable, and plateaus are common even when the medicine is working as expected. Weighing yourself under identical conditions (same time of day, same day of the week) gives a more honest picture than daily fluctuations. Monday mornings work well for many people, though if Monday happens to fall near payday and a weekend of eating out, a Tuesday weigh-in tells you just as much.

For those who find Mounjaro does not produce the expected results, it is also worth reading about why Mounjaro may not work for everyone, there are identifiable patterns, not just random variation.

Step 4: what a clinical assessment at a regulated service covers

Because results depend so heavily on individual circumstances, the clinical assessment before prescribing is not a formality. A GPhC-registered Independent Prescriber reviews your health history, current medicines, BMI, and any weight-related conditions to judge whether Mounjaro is likely to be appropriate and safe for you. That same review happens before every repeat order, not just the first one.

At nume, that review is done by a real prescriber the same day you submit your consultation (orders placed before 12pm are dispatched the same working day once approved). The NICE appraisal of tirzepatide (TA1026) underpins how licensed eligibility criteria are applied, including the six-month progress checkpoint. If you have questions about cost alongside clinical assessment, our guide to Mounjaro pricing in the UK explains what a legitimate private prescription actually includes.

Weight loss is shaped by biology, not willpower, and the right treatment is one that fits your health picture specifically. If you want a prescriber to look at yours, the best next step is straightforward.

Start your free consultation and a GPhC-registered prescriber will review your case the same day.